

ASTCT Pharmacy SIG Journal Club Session – September 9, 2021

PRESENTERS & ARTICLES

Rebecca Rezac, PharmD

PGY2 Oncology Resident
UCHealth

rebecca.rezac@uchealth.org

- Safety and Tolerability of SARS-CoV2 Emergency-Use Authorized Vaccines for Allogeneic Hematopoietic Stem Cell Transplant Recipients ([https://www.astctjournal.org/article/S2666-6367\(21\)01073-3/fulltext](https://www.astctjournal.org/article/S2666-6367(21)01073-3/fulltext))

Emily Ketchum, PharmD

PGY-2 Oncology Pharmacy Resident
Augusta University Medical Center

eketchum@augusta.edu

- Belumosudil for Chronic Graft-versus-Host Disease (cGVHD) After 2 or More Prior Lines of Therapy: The ROCKstar Study (<https://ashpublications.org/blood/article-abstract/doi/10.1182/blood.2021012021/476399/Belumosedil-for-Chronic-Graft-versus-Host-Disease?redirectedFrom=fulltext>)

Session Learning Objectives:

Upon completion of the activity, participants should be able to:

1. Discuss recent BMT pharmacy studies and their applications to current practice.
2. Identify efficacy of SARS-CoV-2 vaccination and vaccine adverse events in patients receiving vaccination for SARS-CoV-2 following allogeneic hematopoietic stem cell transplant.
3. Describe evidence supporting belumosudil for chronic graft-versus-host disease (cGVHD) and identify current place in therapy and clinical implications of belumosudil

TARGET AUDIENCE

This activity is intended for pharmacists.

ACCREDITED PROVIDER

This activity is jointly provided by The France Foundation and ASTCT



CREDIT DESIGNATION

Pharmacists



The France Foundation is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education and will award 1.0 CEU to pharmacists who complete the activity, complete the registration and evaluation forms, and successfully pass a posttest (>75%). There is no fee to participate in this activity. This is a knowledge-based educational activity. Your CE credits will be submitted electronically to the CPE Monitor. CE providers must upload participant information within 60 days from the date the participant completed the activity. **Please submit all evaluations and credit requests no later than 30 days after you complete this activity to ensure your credit fulfillment, as CE credit cannot be awarded past 60 days from the activity date.**
ACPE No. UAN: 0391-9999-21-174-L01-P.

DISCLOSURE POLICY

In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) and the American Society for Transplantation and Cellular Therapy (ASTCT) that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF and ASTCT resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF and ASTCT seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF and ASTCT are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Activity Staff Disclosures

The planners, reviewers, editors, staff, CME committee, or other members at The France Foundation who control content have no relevant financial relationships to disclose.

The planners, reviewers, editors, staff, CME committee, or other members at the American Society for Transplantation and Cellular who control content have no relevant financial relationships to disclose.

Faculty Disclosures

The faculty listed below report that they have no relevant financial relationships to disclose:

- Rebecca Rezac, PharmD
- Emily Ketchum, PharmD

DISCLOSURE OF UNLABELED USE

TFF and ASTCT require CE faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF and ASTCT do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

DISCLAIMER

TFF and ASTCT present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of

their own clinical judgment and accepted standards of care. The France Foundation and ASTCT assume no liability for the information herein.

CONTACT INFORMATION

If you have questions about this CE activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.